FGFR inhibition in urothelial carcinoma
Background and objective The 2024 US Food and Drug Administration approval of
erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations …
erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations …
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
Background and objective Advances in molecular diagnostics have ushered in a new era for
patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular …
patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular …
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
X Li, T Liu, A Bacchiocchi, M Li, W Cheng… - EMBO Molecular …, 2024 - embopress.org
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise
for detection of molecular residual disease (MRD), its performance is limited by WGS error …
for detection of molecular residual disease (MRD), its performance is limited by WGS error …
[HTML][HTML] Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment
G Crisafulli - Genes, 2025 - pmc.ncbi.nlm.nih.gov
This review provides a comprehensive overview of the evolving role of minimal residual
disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for …
disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for …
[HTML][HTML] Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease
Background and objective Circulating tumor DNA (ctDNA) testing provides valuable
prognostic and predictive information for guiding therapeutic choices and monitoring …
prognostic and predictive information for guiding therapeutic choices and monitoring …
Cross-dataset pan-cancer detection: Correlating cell-free DNA fragment coverage with open chromatin sites across cell types
LR Olsen, D Odinokov, JQ Holsting, K Kondrup… - medRxiv, 2024 - medrxiv.org
The fragmentation patterns of whole genome sequenced cell-free DNA are promising
features for tumor-agnostic cancer detection. However, systematic biases challenge their …
features for tumor-agnostic cancer detection. However, systematic biases challenge their …
Low T cell diversity is associated with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire
A Kjær, N Kristjánsdóttir, RI Juul, I Nordentoft… - bioRxiv, 2024 - biorxiv.org
T cells are one of the primary effector cells in the endogenous defense against cancer, yet
the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we …
the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we …
[PDF][PDF] Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer
SV Lindskrog, L Dyrskjøt - Translational Andrology and Urology, 2024 - cdn.amegroups.cn
Correspondence to: Lars Dyrskjøt, MSc, PhD. Department of Clinical Medicine, Aarhus
University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University …
University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University …
Re: Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, et al. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor …
X Wu, X Yao, Z Chen, H Xu - European urology, 2024 - pubmed.ncbi.nlm.nih.gov
Re: Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, et al. Whole-genome
Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with …
Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with …
Blasenkarzinom: Detektion zirkulierender Tumor-DNA mittels Gesamt-Genom-Sequenzierung
J Lorenz - Aktuelle Urologie, 2025 - thieme-connect.com
Nahezu die Hälfte der kurativ behandelten muskelinvasiven Blasenkarzinome rezidiviert.
Zirkulierende Tumor-DNA (ctDNA) bietet sich zur Detektion der minimalen Resterkrankung …
Zirkulierende Tumor-DNA (ctDNA) bietet sich zur Detektion der minimalen Resterkrankung …